Back to Search Start Over

Blockbuster forecasts in psoriasis, AF markets.

Source :
PharmacoEconomics & Outcomes News; 9/23/2006, Issue 512, p10-10, 1/3p
Publication Year :
2006

Abstract

The article offers information on forecasts on the status of etanercept, rivaroxaban and dabigatran etexilate in the psoriasis and atrial fibrillation (AF) market by 2015. Several countries in which etanercept will achieve blockbuster status include France and Germany. The predicted percentage increase in the number of AF patients receiving anticoagulants is cited.

Subjects

Subjects :
ETANERCEPT
PSORIASIS
SELLING of drugs
ATRIAL fibrillation
ANTICOAGULANTS

Details

Language :
English
ISSN :
11735503
Issue :
512
Database :
Complementary Index
Journal :
PharmacoEconomics & Outcomes News
Publication Type :
Periodical
Accession number :
23006373
Full Text :
https://doi.org/10.2165/00151234-200605120-00026
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details